Re: “Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized,Double-Blind,Placebo-Controlled Clinical Trial” by Crippa et al.

Crippa JAS , Pacheco JC , Zuardi AW , et al. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE Study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis Cannabinoid Res. 2021 [Epub ahead of print]; DOI: 10.1089/can.2021.0093.

Nguyen LC , Yang D , Nicolaescu V , et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022; 8:eabi6110. DOI: 10.1126/sciadv.abi6110.

Henson JD , Vitetta L , Quezada M , et al. Enhancing endocannabinoid control of stress with cannabidiol. J Clin Med. 2021; 10:5852.

Chen J , Hall S , Vitetta L . Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021; 31:1–13.

Ng S , Haran J . Gut bacteria linked with long COVID. MDedge. https://www.mdedge.com/internalmedicine/article/251080/covid-19-updates/gut-bacteria-linked-long-covid Accessed January 25, 2022.

Crippa JAS , Zuardi AW , Guimarães FS , et al. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw Open. 2021; 4:e2120603.

Lian J , Casari I , Falasca M . Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract. Pharmacol Res. 2022; 175:106025.

Bruni N , Della Pepa C , Oliaro-Bosso S , et al. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018; 23:2478.

Liu Z , Martin JH . Gaps in predicting clinical doses for cannabinoids therapy: overview of issues for pharmacokinetics and pharmacodynamics modelling. Br J Clin Pharmacol. 2018; 84:2483–2487.

Lucas CJ , Galettis P , Schneider J . The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018; 84:2477–2482.

Grotenhermen F . Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003; 42:327–360.

Karschner EL , Darwin WD , Goodwin RS , et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011; 57:66–75.

Sun Z , Song ZG , Liu C , et al. Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med. 2022; 20:24.

Chen J , Vitetta L , Henson JD , et al. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. J Funct Foods. 2021; 87:104850.